Shares of United Therapeutics shot up to $406.42 during today's afternoon trading session -- an increase of 33.4% that brings the stock 6.79% over its average analyst target price of $380.57. This may imply limited upside for the Pharmaceutical stock, whose analysts give it a consensus rating of buy, and target prices spanning from $295.0 to $510.0 dollars per share.
We can use United Therapeutics's short interest as a proxy for determining general market sentiment regarding the stock. The short interest is the percentage of the share float that represents short positions, meaning that the investor believes the stock will decline in the future. Since UTHR's short interest is 8.3%, the market sentiment is mixed on this stock.
Short selling involves borrowing shares and then selling them at current market prices. In the successful version of the strategy, the shares are purchased at a lower price at some time in the future. The investor then returns the shares to the lender, and keeps the profit made on the sell/buy transaction.
Another way to gauge the sentiment on United Therapeutics is to look at the percentage of institutions that are invested in the stock. In this case, 99.5% of the shares are held by pension, mutual, and hedge funds, which shows that these institutions probably have strong confidence in the stock.
If institutions are invested in a particular stock, it shows in most cases that they have performed quality research and concluded that it is a good investment. In some cases, however, increases in institutional ownership could be a sign of a takeover attempt or proxy fight, which can actually injure share prices. Also, institutions are not infallible, and can certainly make miscalculations -- often with spectacular results.
Overall, there is mixed market sentiment on United Therapeutics because its an analyst consensus of little upside potential, a buy rating, an above average percentage of its shares sold short, and a significant number of institutional investors. Warren Buffett famously said that in the short term, markets are voting mechanisms, but in the long term, they are weighing mechanisms. This means that long term investors should be aware of a stock's fundamentals before committing.
Buffett was one of the fist investors to focus on free cash flow as a yardstick for a company's health. Here are UTHR's recent cash flows:
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 1,327,100 | 246,500 | 1,080,600 | 44.54 |
| 2023 | 978,000 | 230,400 | 747,600 | 12.64 |
| 2022 | 802,500 | 138,800 | 663,700 | 39.02 |
| 2021 | 598,200 | 120,800 | 477,400 | -31.45 |
| 2020 | 755,700 | 59,300 | 696,400 | 339.89 |
| 2019 | -206,600 | 83,700 | -290,300 |
